Karyopharm Therapeutics | KPTI - Cost Of Sales


Karyopharm Therapeutics reported $1.34M in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
AbbVie USD 4.29B 73M Jun/2026
Abbott USD 5.94B 642M Jun/2026
Amgen USD 1.87B 271M Jun/2026
AstraZeneca USD 2.52B 2.73B Jun/2026
BioCryst Pharmaceuticals USD 3.84M 5.68M Jun/2026
Bristol-Myers Squibb USD 7.89B 4.03B Jun/2026
Eli Lilly USD 3.27B 309M Jun/2026
GlaxoSmithKline GBP 2.07B 192M Jun/2026
Incyte USD 104.96M 457K Jun/2026
J&J USD 8B 67M Jun/2026
Karyopharm Therapeutics USD 1.34M 139K Mar/2026
MacroGenics USD 9.53M 585K Mar/2026
Merck USD 3.14B 200M Jun/2026
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Novartis USD 3.71B 251M Jun/2026
Novartis USD 3.46B 83M Mar/2026
Pfizer USD 4.09B 498M Jun/2026
Regeneron Pharmaceuticals USD 576.5M 92.9M Jun/2026
Roche Holding CHF 7.85B 630M Jun/2026
Sangamo BioSciences 2.42M 1.11M Jun/2024
Takeda JPY 517.6B 42.94B Jun/2026
TG Therapeutics USD 41.19M 7.68M Jun/2026
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
Xencor USD 61.66M 50.95M Jun/2025